Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 10MG
USFDA APPLICATION NUMBER - 21518
DOSAGE - TABLET;ORAL - 5MG
USFDA APPLICATION NUMBER - 21518
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
64
PharmaCompass offers a list of Solifenacin Succinate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Solifenacin Succinate manufacturer or Solifenacin Succinate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Solifenacin Succinate manufacturer or Solifenacin Succinate supplier.
A YM67905 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of YM67905, including repackagers and relabelers. The FDA regulates YM67905 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. YM67905 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of YM67905 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A YM67905 supplier is an individual or a company that provides YM67905 active pharmaceutical ingredient (API) or YM67905 finished formulations upon request. The YM67905 suppliers may include YM67905 API manufacturers, exporters, distributors and traders.
click here to find a list of YM67905 suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A YM67905 DMF (Drug Master File) is a document detailing the whole manufacturing process of YM67905 active pharmaceutical ingredient (API) in detail. Different forms of YM67905 DMFs exist exist since differing nations have different regulations, such as YM67905 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A YM67905 DMF submitted to regulatory agencies in the US is known as a USDMF. YM67905 USDMF includes data on YM67905's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The YM67905 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of YM67905 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The YM67905 Drug Master File in Japan (YM67905 JDMF) empowers YM67905 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the YM67905 JDMF during the approval evaluation for pharmaceutical products. At the time of YM67905 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of YM67905 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a YM67905 Drug Master File in Korea (YM67905 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of YM67905. The MFDS reviews the YM67905 KDMF as part of the drug registration process and uses the information provided in the YM67905 KDMF to evaluate the safety and efficacy of the drug.
After submitting a YM67905 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their YM67905 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of YM67905 suppliers with KDMF on PharmaCompass.
A YM67905 CEP of the European Pharmacopoeia monograph is often referred to as a YM67905 Certificate of Suitability (COS). The purpose of a YM67905 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of YM67905 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of YM67905 to their clients by showing that a YM67905 CEP has been issued for it. The manufacturer submits a YM67905 CEP (COS) as part of the market authorization procedure, and it takes on the role of a YM67905 CEP holder for the record. Additionally, the data presented in the YM67905 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the YM67905 DMF.
A YM67905 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. YM67905 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of YM67905 suppliers with CEP (COS) on PharmaCompass.
A YM67905 written confirmation (YM67905 WC) is an official document issued by a regulatory agency to a YM67905 manufacturer, verifying that the manufacturing facility of a YM67905 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting YM67905 APIs or YM67905 finished pharmaceutical products to another nation, regulatory agencies frequently require a YM67905 WC (written confirmation) as part of the regulatory process.
click here to find a list of YM67905 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing YM67905 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for YM67905 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture YM67905 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain YM67905 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a YM67905 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of YM67905 suppliers with NDC on PharmaCompass.
YM67905 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of YM67905 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right YM67905 GMP manufacturer or YM67905 GMP API supplier for your needs.
A YM67905 CoA (Certificate of Analysis) is a formal document that attests to YM67905's compliance with YM67905 specifications and serves as a tool for batch-level quality control.
YM67905 CoA mostly includes findings from lab analyses of a specific batch. For each YM67905 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
YM67905 may be tested according to a variety of international standards, such as European Pharmacopoeia (YM67905 EP), YM67905 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (YM67905 USP).
